Unknown

Dataset Information

0

Phenotyping of UGT1A1 Activity Using Raltegravir Predicts Pharmacokinetics and Toxicity of Irinotecan in FOLFIRI.


ABSTRACT: BACKGROUND:Irinotecan toxicity correlates with UGT1A1 activity. We explored whether phenotyping UGT1A1 using a probe approach works better than current genotyping methods. METHODS:Twenty-four Asian cancer patients received irinotecan as part of the FOLFIRI regimen. Subjects took raltegravir 400 mg orally and intravenous midazolam 1 mg. Pharmacokinetic analyses were performed using WinNonLin and NONMEM. Genomic DNA was isolated and screened for the known genetic variants in UGT1A1 and CYP3A4/5. RESULTS:SN-38G/SN-38 AUC ratio correlated well with Raltegravir glucuronide/ Raltegravir AUC ratio (r = 0.784 p<0.01). Midazolam clearance correlated well with irinotecan clearance (r = 0.563 p<0.01). SN-38 AUC correlated well with Log10Nadir Absolute Neutrophil Count (ANC) (r = -0.397 p<0.05). Significant correlation was found between nadir ANC and formation rate constant of raltegravir glucuronide (r = 0.598, P<0.005), but not UGT1A1 genotype. CONCLUSION:Raltegravir glucuronide formation is a good predictor of nadir ANC, and can predict neutropenia in East Asian patients. Prospective studies with dose adjustments should be done to develop raltegravir as a probe to optimize irinotecan therapy. TRIAL REGISTRATION:Clinicaltrials.gov NCT00808184.

SUBMITTER: Lee LS 

PROVIDER: S-EPMC4726617 | biostudies-literature | 2016

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC3699040 | biostudies-literature
| S-EPMC10901933 | biostudies-literature
| S-EPMC5497725 | biostudies-literature
| S-EPMC2768885 | biostudies-literature
| S-EPMC9283744 | biostudies-literature
| S-EPMC5488790 | biostudies-other
| S-EPMC4213295 | biostudies-literature
| S-EPMC5338934 | biostudies-other
| S-EPMC9584256 | biostudies-literature
| S-EPMC5522258 | biostudies-other